VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo

C. M. Lee, M. M. Hickey, C. A. Sanford, C. G. McGuire, C. L. Cowey, M. C. Simon, W. K. Rathmell

Research output: Contribution to journalArticlepeer-review

33 Scopus citations


Von Hippel-Lindau (VHL) disease is caused by germline mutations in the VHL tumor suppressor gene, with Type 2B missense VHL mutations predisposing to renal cell carcinoma, hemangioblastoma and pheochromocytoma. Type 2B mutant pVHL is predicted to be defective in hypoxia inducible factor (HIF)-α regulation. Murine embryonic stem (ES) cells in which the endogenous wild-type Vhl gene was replaced with the representative Type 2B VHL hotspot mutation R167Q (Vhl 2B/2B) displayed preserved physiological regulation of both HIF factors with slightly greater normoxic dysregulation of HIF-2α. Differentiated Vhl 2B/2B -derived teratomas overexpressed joint HIF targets Vegf and EglN3 but not the HIF-1α-specific target Pfk1. Vhl 2B/2B teratomas additionally displayed a growth advantage over Vhl / -derived teratomas, suggestive of a tight connection between perturbations in the degree and ratio of HIF-1α and HIF-2α stabilization and cell growth. Vhl 2B/2B mice displayed mid-gestational embryonic lethality, whereas adult Vhl 2B/ mice exhibited susceptibility to carcinogen-promoted renal neoplasia compared with wild-type littermates at 12 months. Our experiments support a model in which the representative Type 2B R167Q mutant pVhl produces a unique profile of HIF dysregulation, thereby promoting tissue-specific effects on cell growth, development and tumor predisposition.

Original languageEnglish
Pages (from-to)1694-1705
Number of pages12
Issue number14
StatePublished - Apr 9 2009


  • Hypoxia inducible factors
  • Renal cell carcinoma
  • Von HippelLindau


Dive into the research topics of 'VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo'. Together they form a unique fingerprint.

Cite this